Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NCT05932264 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Non-small Cell Lung Cancer

Interventions

DRUG: Apatinib + Fluzoparib
DRUG: Apatinib + Fluzoparib + Adebrelimab

Sponsor

Sun Yat-sen University